Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward

Area of Science:

• Genetics and Molecular Biology
• Pulmonology and Respiratory Medicine
• Gene Therapy and Vector Design

Background:

• Cystic Fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in the CFTR gene, leading to progressive lung disease and early mortality.
• The majority of CF patients have the ΔF508 mutation, but numerous other CFTR mutations exist, causing varied disease severity.
• Lung disease, characterized by chronic infection and inflammation, is the primary cause of death in individuals with CF.

Purpose of the Study:

• To review the historical development of gene therapy for Cystic Fibrosis (CF).
• To discuss the challenges and advancements in CFTR gene replacement strategies.
• To explore current state-of-the-art gene delivery vector designs for CF treatment.

Main Methods:

• Historical review of CF gene therapy research from gene discovery to clinical trials.
• Analysis of in vitro and in vivo studies demonstrating the feasibility of CFTR gene correction.
• Examination of various gene delivery vectors and their efficacy in preclinical and clinical settings.

Main Results:

• Proof-of-concept for CFTR gene therapy was established in vitro in 1990, shortly after the gene's discovery in 1989.
• Numerous clinical trials have been conducted since 1993, but no FDA-approved gene therapy for CF is currently available.
• Despite significant challenges in clinical implementation, ongoing innovation in gene delivery vectors shows promise.

Conclusions:

• A CFTR gene replacement approach holds potential efficacy for all CF-causing mutations.
• The clinical translation of CF gene therapy has faced more obstacles than initially anticipated.
• Continued advancements in gene therapy technology offer hope for future FDA approval and effective treatment of CF lung disease.